Skip to main content
Top
Published in: Hepatology International 3/2012

01-06-2012 | Original Article

Host genetic variants and hepatitis B virologic features in HBeAg-negative hepatitis B carriers with long-term biochemical remission

Authors: Chih-Lin Lin, Tai-Chung Tseng, Tung-Hung Su, Chun-Jen Liu, Pei-Jer Chen, Ming-Yang Lai, Ding-Shinn Chen, Jia-Horng Kao

Published in: Hepatology International | Issue 3/2012

Login to get access

Abstract

Purpose

A significant portion of HBeAg-negative chronic hepatitis B patients have persistently normal serum alanine aminotransferase levels (PNALT). We thus investigated host genetic variants and virological features in HBeAg-negative hepatitis B carriers.

Methods

Baseline clinical and virological features of 133 HBeAg-negative hepatitis B carriers (77 with PNALT and 56 with chronic hepatitis activity) with follow-up for more than 5 years were investigated. Three single nucleotide polymorphisms (SNPs) located within or around human leukocyte antigen (HLA)-DPA1, HLA-DPB1, and interleukin (IL) 28B loci were genotyped.

Results

The genotype frequencies of these SNPs were comparable between hepatitis B carriers with PNALT and those with chronic hepatitis. Compared with hepatitis B carriers with PNALT, those with chronic hepatitis had significantly higher baseline serum HBV-DNA levels (4.96 vs. 4.04 log10 IU/ml, P = 0.001). Baseline serum HBV-DNA level > 2000 IU/ml (OR, 8.42; 95% CI, 2.74–25.90, P < 0.001) were the only independent factor associated with chronic hepatitis activity. Changes of serum HBV-DNA in 30 hepatitis B carriers with PNALT had showed a significant reduction of viral load from baseline to last visit (mean difference of paired HBV-DNA levels: −0.78 log10 IU/ml, 95% CI: −1.57 to −0.013, P = 0.047). In contrast, no significant reduction of viral load was found in 28 patients with chronic hepatitis.

Conclusions

The results indicate that lower baseline serum HBV-DNA level and viral load reduction over time are associated with long-term biochemical remission in HBeAg-negative hepatitis B carriers.
Literature
1.
2.
go back to reference Kao JH, Chen DS. Changing disease burden of hepatocellular carcinoma in the Far East and Southeast Asia. Liver Int 2005;25:696–703PubMedCrossRef Kao JH, Chen DS. Changing disease burden of hepatocellular carcinoma in the Far East and Southeast Asia. Liver Int 2005;25:696–703PubMedCrossRef
4.
go back to reference Yim HJ, Lok AS. Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005. Hepatology 2006;43:S173–S181PubMedCrossRef Yim HJ, Lok AS. Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005. Hepatology 2006;43:S173–S181PubMedCrossRef
5.
go back to reference Chu CM, Liaw YF. Incidence and risk factors of progression to cirrhosis in inactive carriers of hepatitis B virus. Am J Gastroenterol 2006;104:1693–1699CrossRef Chu CM, Liaw YF. Incidence and risk factors of progression to cirrhosis in inactive carriers of hepatitis B virus. Am J Gastroenterol 2006;104:1693–1699CrossRef
6.
go back to reference Papatheodoridis GV, Hadziyannis SJ. Diagnosis and management of precore mutant chronic hepatitis B. J Viral Hepat 2001;8:311–321PubMedCrossRef Papatheodoridis GV, Hadziyannis SJ. Diagnosis and management of precore mutant chronic hepatitis B. J Viral Hepat 2001;8:311–321PubMedCrossRef
7.
go back to reference Brunetto MR, Oliveri F, Coco B, et al. Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long-term cohort study. J Hepatol 2002;36:263–270PubMedCrossRef Brunetto MR, Oliveri F, Coco B, et al. Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long-term cohort study. J Hepatol 2002;36:263–270PubMedCrossRef
9.
go back to reference Kumar M, Sarin SK, Hissar S, et al. Virological and histological features of chronic hepatitis B virus infected asymptomatic patients with persistently normal ALT. Gastroenterology 2008;134:1376–1384PubMedCrossRef Kumar M, Sarin SK, Hissar S, et al. Virological and histological features of chronic hepatitis B virus infected asymptomatic patients with persistently normal ALT. Gastroenterology 2008;134:1376–1384PubMedCrossRef
10.
go back to reference Lin CL, Liao LY, Liu CJ, et al. Hepatitis B viral factors in HBeAg negative carriers with persistently normal serum alanine aminotransferase levels. Hepatology 2007;45:1193–1198PubMedCrossRef Lin CL, Liao LY, Liu CJ, et al. Hepatitis B viral factors in HBeAg negative carriers with persistently normal serum alanine aminotransferase levels. Hepatology 2007;45:1193–1198PubMedCrossRef
11.
go back to reference Frodsham AJ. Host genetics and the outcome of hepatitis B viral infection. Transpl Immunol 2005;14:183–186PubMedCrossRef Frodsham AJ. Host genetics and the outcome of hepatitis B viral infection. Transpl Immunol 2005;14:183–186PubMedCrossRef
12.
go back to reference Kamatani Y, Wattanapokayakit S, Ochi H, et al. A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians. Nat Genet 2009;41:591–595PubMedCrossRef Kamatani Y, Wattanapokayakit S, Ochi H, et al. A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians. Nat Genet 2009;41:591–595PubMedCrossRef
13.
go back to reference Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009;461:798–801PubMedCrossRef Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009;461:798–801PubMedCrossRef
14.
go back to reference Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009;461:399–401PubMedCrossRef Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009;461:399–401PubMedCrossRef
15.
go back to reference Yeh SH, Tsai CY, Kao JH, et al. Quantification and genotyping of hepatitis B virus in a single reaction by real-time PCR and melting curve analysis. J Hepatol 2004;41:659–666PubMedCrossRef Yeh SH, Tsai CY, Kao JH, et al. Quantification and genotyping of hepatitis B virus in a single reaction by real-time PCR and melting curve analysis. J Hepatol 2004;41:659–666PubMedCrossRef
16.
go back to reference Kao JH, Chen PJ, Lai MY, Chen DS. Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers. Gastroenterology 2003;124:327–334PubMedCrossRef Kao JH, Chen PJ, Lai MY, Chen DS. Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers. Gastroenterology 2003;124:327–334PubMedCrossRef
17.
go back to reference Wigginton JE, Cutler DJ, Abecasis GR. A note on exact tests of Hardy–Weinberg equilibrium. Am J Hum Genet 2005;76:887–893PubMedCrossRef Wigginton JE, Cutler DJ, Abecasis GR. A note on exact tests of Hardy–Weinberg equilibrium. Am J Hum Genet 2005;76:887–893PubMedCrossRef
18.
go back to reference Dudbridge F. Likelihood-based association analysis for nuclear families and unrelated subjects with missing genotype data. Hum Hered 2008;66:87–98PubMedCrossRef Dudbridge F. Likelihood-based association analysis for nuclear families and unrelated subjects with missing genotype data. Hum Hered 2008;66:87–98PubMedCrossRef
19.
go back to reference Hadziyannis SJ, Vassilopoulos D. Hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2001;34:617–624PubMedCrossRef Hadziyannis SJ, Vassilopoulos D. Hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2001;34:617–624PubMedCrossRef
20.
go back to reference Bonino F, Brunetto MR. Chronic hepatitis B e antigen (HBeAg) negative, anti-HBe positive hepatitis B: an overview. J Hepatol 2003;39:S160–S163PubMedCrossRef Bonino F, Brunetto MR. Chronic hepatitis B e antigen (HBeAg) negative, anti-HBe positive hepatitis B: an overview. J Hepatol 2003;39:S160–S163PubMedCrossRef
21.
go back to reference Kumar M, Chauhan R, Gupta N, Hissar S, Sakhuja P, Sarin SK. Spontaneous increases in alanine aminotransferase levels in asymptomatic chronic hepatitis B virus-infected patients. Gastroenterology 2009;136:1272–1280PubMedCrossRef Kumar M, Chauhan R, Gupta N, Hissar S, Sakhuja P, Sarin SK. Spontaneous increases in alanine aminotransferase levels in asymptomatic chronic hepatitis B virus-infected patients. Gastroenterology 2009;136:1272–1280PubMedCrossRef
22.
go back to reference Lin CL, Liao LY, Wang CS, et al. Basal core promoter mutant of hepatitis B virus and progression of liver disease in HBeAg negative chronic hepatitis B. Liver Int 2005;25:564–570PubMedCrossRef Lin CL, Liao LY, Wang CS, et al. Basal core promoter mutant of hepatitis B virus and progression of liver disease in HBeAg negative chronic hepatitis B. Liver Int 2005;25:564–570PubMedCrossRef
23.
go back to reference Chu CM, Liaw YF. Spontaneous relapse of hepatitis in inactive HBsAg carriers from Taiwan. Hepatol Int 2007;1:311–315PubMedCrossRef Chu CM, Liaw YF. Spontaneous relapse of hepatitis in inactive HBsAg carriers from Taiwan. Hepatol Int 2007;1:311–315PubMedCrossRef
24.
go back to reference Chu CM, Liaw YF. Predictive factors for reactivation of hepatitis B following hepatitis B e antigen seroconversion in chronic hepatitis B. Gastroenterology 2007;133:1458–465PubMedCrossRef Chu CM, Liaw YF. Predictive factors for reactivation of hepatitis B following hepatitis B e antigen seroconversion in chronic hepatitis B. Gastroenterology 2007;133:1458–465PubMedCrossRef
25.
go back to reference Feld JJ, Ayers M, El-Ashry D, Mazzulli T, Tellier R, Heathcote EJ. Hepatitis B virus DNA prediction rules for hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2007;46:1057–1070PubMedCrossRef Feld JJ, Ayers M, El-Ashry D, Mazzulli T, Tellier R, Heathcote EJ. Hepatitis B virus DNA prediction rules for hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2007;46:1057–1070PubMedCrossRef
26.
go back to reference Papatheodoridis GV, Chrysanthos N, Hadziyannis E, Cholongitas E, Manesis EK. Longitudinal changes in serum HBV-DNA levels and predictors of progression during the natural course of HBeAg-negative chronic hepatitis B virus infection. J Viral Hepat 2008;15:434–441PubMedCrossRef Papatheodoridis GV, Chrysanthos N, Hadziyannis E, Cholongitas E, Manesis EK. Longitudinal changes in serum HBV-DNA levels and predictors of progression during the natural course of HBeAg-negative chronic hepatitis B virus infection. J Viral Hepat 2008;15:434–441PubMedCrossRef
27.
go back to reference Chen CJ, Yang HI, REVEAL-HBV Study Group, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65–73PubMedCrossRef Chen CJ, Yang HI, REVEAL-HBV Study Group, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65–73PubMedCrossRef
28.
go back to reference Papatheodoridis GV, Manesis EK, Manolakopoulos S, et al. Is there a meaningful serum hepatitis B virus DNA cutoff level for therapeutic decisions in hepatitis B e antigen-negative chronic hepatitis B virus infection? Hepatology 2008;48:1451–459PubMedCrossRef Papatheodoridis GV, Manesis EK, Manolakopoulos S, et al. Is there a meaningful serum hepatitis B virus DNA cutoff level for therapeutic decisions in hepatitis B e antigen-negative chronic hepatitis B virus infection? Hepatology 2008;48:1451–459PubMedCrossRef
29.
go back to reference Tong S, Kim KH, Chante C, Wands J, Li J. Hepatitis B virus e antigen variants. Int J Med Sci 2005;2:2–7PubMedCrossRef Tong S, Kim KH, Chante C, Wands J, Li J. Hepatitis B virus e antigen variants. Int J Med Sci 2005;2:2–7PubMedCrossRef
30.
go back to reference Liu CJ, Chen BF, Chen PJ, et al. Role of hepatitis B viral load and basal core promoter mutation in hepatocellular carcinoma in hepatitis B carriers. J Infect Dis 2006;193:1258–1265PubMedCrossRef Liu CJ, Chen BF, Chen PJ, et al. Role of hepatitis B viral load and basal core promoter mutation in hepatocellular carcinoma in hepatitis B carriers. J Infect Dis 2006;193:1258–1265PubMedCrossRef
31.
go back to reference Liu CJ, Chen BF, Chen PJ, et al. Role of hepatitis B virus precore/core promoter mutations and serum viral load on noncirrhotic hepatocellular carcinoma: a case–control study. J Infect Dis 2006;194:594–599PubMedCrossRef Liu CJ, Chen BF, Chen PJ, et al. Role of hepatitis B virus precore/core promoter mutations and serum viral load on noncirrhotic hepatocellular carcinoma: a case–control study. J Infect Dis 2006;194:594–599PubMedCrossRef
32.
go back to reference Chen BF, Liu CJ, Jow GM, Chen PJ, Kao JH, Chen DS. High prevalence and mapping of pre-S deletion in hepatitis B virus carriers with progressive liver diseases. Gastroenterology 2006;130:1153–1168PubMedCrossRef Chen BF, Liu CJ, Jow GM, Chen PJ, Kao JH, Chen DS. High prevalence and mapping of pre-S deletion in hepatitis B virus carriers with progressive liver diseases. Gastroenterology 2006;130:1153–1168PubMedCrossRef
33.
go back to reference Liu S, Zhang H, Gu C, et al. Associations between hepatitis B virus mutations and the risk of hepatocellular carcinoma: a meta-analysis. J Natl Cancer Inst 2009;101:1066–1082PubMedCrossRef Liu S, Zhang H, Gu C, et al. Associations between hepatitis B virus mutations and the risk of hepatocellular carcinoma: a meta-analysis. J Natl Cancer Inst 2009;101:1066–1082PubMedCrossRef
34.
go back to reference Tseng TC, Yu ML, Liu CJ, et al. (2011) Impact of host and viral factors on HBeAg-positive chronic hepatitis B patients receiving peginterferon alfa-2a therapy. Antivir Ther Tseng TC, Yu ML, Liu CJ, et al. (2011) Impact of host and viral factors on HBeAg-positive chronic hepatitis B patients receiving peginterferon alfa-2a therapy. Antivir Ther
Metadata
Title
Host genetic variants and hepatitis B virologic features in HBeAg-negative hepatitis B carriers with long-term biochemical remission
Authors
Chih-Lin Lin
Tai-Chung Tseng
Tung-Hung Su
Chun-Jen Liu
Pei-Jer Chen
Ming-Yang Lai
Ding-Shinn Chen
Jia-Horng Kao
Publication date
01-06-2012
Publisher
Springer-Verlag
Published in
Hepatology International / Issue 3/2012
Print ISSN: 1936-0533
Electronic ISSN: 1936-0541
DOI
https://doi.org/10.1007/s12072-011-9297-4

Other articles of this Issue 3/2012

Hepatology International 3/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.